William Michael Lin, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anthelmintics | 1 | 2018 | 83 | 0.600 |
Why?
|
| Gene Dosage | 3 | 2011 | 1218 | 0.590 |
Why?
|
| Helminthiasis | 1 | 2018 | 81 | 0.580 |
Why?
|
| Melanoma | 7 | 2018 | 5709 | 0.490 |
Why?
|
| Nevus | 2 | 2014 | 205 | 0.440 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 560 | 0.420 |
Why?
|
| Drug Utilization | 1 | 2018 | 1188 | 0.400 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 2011 | 212 | 0.400 |
Why?
|
| Skin Neoplasms | 7 | 2019 | 5821 | 0.390 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 592 | 0.360 |
Why?
|
| Mycosis Fungoides | 2 | 2011 | 170 | 0.330 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2811 | 0.250 |
Why?
|
| Oncogenes | 5 | 2011 | 1222 | 0.240 |
Why?
|
| Immunity, Innate | 1 | 2016 | 3066 | 0.230 |
Why?
|
| Genetic Markers | 1 | 2010 | 2601 | 0.220 |
Why?
|
| Leukemia | 1 | 2011 | 1522 | 0.210 |
Why?
|
| Immunotherapy | 1 | 2016 | 4651 | 0.180 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 5440 | 0.180 |
Why?
|
| raf Kinases | 2 | 2011 | 118 | 0.160 |
Why?
|
| Mebendazole | 1 | 2018 | 1 | 0.160 |
Why?
|
| Albendazole | 1 | 2018 | 50 | 0.160 |
Why?
|
| Signal Transduction | 3 | 2016 | 23447 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2016 | 1745 | 0.140 |
Why?
|
| Genomics | 2 | 2011 | 5821 | 0.130 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2016 | 197 | 0.130 |
Why?
|
| Graft vs Host Reaction | 1 | 2014 | 102 | 0.110 |
Why?
|
| Hemangioma | 1 | 2019 | 727 | 0.110 |
Why?
|
| Niacinamide | 1 | 2014 | 413 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 4 | 2016 | 2057 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 15843 | 0.100 |
Why?
|
| Loss of Heterozygosity | 3 | 2009 | 662 | 0.100 |
Why?
|
| Gene Amplification | 3 | 2011 | 1089 | 0.100 |
Why?
|
| Protein Methyltransferases | 1 | 2011 | 53 | 0.090 |
Why?
|
| Facial Transplantation | 1 | 2014 | 221 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2014 | 529 | 0.090 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2014 | 495 | 0.090 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2014 | 732 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2019 | 2571 | 0.080 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2011 | 330 | 0.080 |
Why?
|
| ras Proteins | 2 | 2011 | 1054 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2011 | 641 | 0.070 |
Why?
|
| Genome, Human | 3 | 2011 | 4425 | 0.070 |
Why?
|
| Mutation | 5 | 2016 | 30054 | 0.070 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2009 | 412 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2008 | 277 | 0.070 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 1062 | 0.070 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2008 | 257 | 0.070 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 2915 | 0.070 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 682 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3639 | 0.070 |
Why?
|
| Chromosome Deletion | 2 | 2008 | 1386 | 0.070 |
Why?
|
| Cell Line, Tumor | 4 | 2011 | 16990 | 0.070 |
Why?
|
| Gene Expression Profiling | 4 | 2011 | 9420 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2009 | 799 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2009 | 1115 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 615 | 0.060 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 934 | 0.060 |
Why?
|
| Chromosome Aberrations | 2 | 2009 | 1768 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2016 | 2865 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 1246 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 1745 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2011 | 2020 | 0.050 |
Why?
|
| Prognosis | 2 | 2014 | 29629 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2011 | 4514 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2008 | 2707 | 0.050 |
Why?
|
| Graft Rejection | 1 | 2014 | 4446 | 0.040 |
Why?
|
| Humans | 18 | 2019 | 761578 | 0.040 |
Why?
|
| Survival Rate | 1 | 2014 | 12725 | 0.040 |
Why?
|
| Tissue Embedding | 1 | 2019 | 42 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 2805 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 4026 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2014 | 3615 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 4111 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2019 | 147 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 58983 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2019 | 615 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2010 | 15936 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 10194 | 0.030 |
Why?
|
| Aged | 5 | 2019 | 169308 | 0.030 |
Why?
|
| Middle Aged | 6 | 2019 | 220917 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 4580 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 9031 | 0.030 |
Why?
|
| Neurofibromin 1 | 1 | 2016 | 190 | 0.030 |
Why?
|
| Transcription Factors | 2 | 2010 | 12130 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 9610 | 0.030 |
Why?
|
| Male | 6 | 2019 | 360841 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 899 | 0.020 |
Why?
|
| Biopsy | 2 | 2016 | 6766 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2011 | 2827 | 0.020 |
Why?
|
| Female | 6 | 2019 | 392688 | 0.020 |
Why?
|
| Animals | 4 | 2016 | 168475 | 0.020 |
Why?
|
| Sezary Syndrome | 1 | 2011 | 80 | 0.020 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2009 | 58 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 6346 | 0.020 |
Why?
|
| Genes, Homeobox | 1 | 2011 | 286 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 2468 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2011 | 638 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 855 | 0.020 |
Why?
|
| Neoplasms | 2 | 2007 | 22172 | 0.020 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2010 | 259 | 0.020 |
Why?
|
| Young Adult | 1 | 2014 | 59254 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2009 | 491 | 0.020 |
Why?
|
| Melanocytes | 1 | 2011 | 509 | 0.020 |
Why?
|
| Algorithms | 1 | 2008 | 14032 | 0.020 |
Why?
|
| Genes, ras | 1 | 2010 | 654 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2007 | 287 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 2009 | 13382 | 0.020 |
Why?
|
| Adult | 3 | 2019 | 221200 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 1739 | 0.020 |
Why?
|
| Child | 1 | 2014 | 80157 | 0.020 |
Why?
|
| Adolescent | 1 | 2014 | 88323 | 0.020 |
Why?
|
| Receptors, Virus | 1 | 2009 | 640 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2011 | 1561 | 0.020 |
Why?
|
| Boston | 1 | 2019 | 9326 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2014 | 80646 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 4915 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 1791 | 0.020 |
Why?
|
| Sex Factors | 1 | 2019 | 10554 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2009 | 1175 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2014 | 2332 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2011 | 8553 | 0.010 |
Why?
|
| Age of Onset | 1 | 2011 | 3306 | 0.010 |
Why?
|
| Interleukin-17 | 1 | 2009 | 912 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2010 | 3614 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 2510 | 0.010 |
Why?
|
| Genotype | 2 | 2007 | 12990 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 1651 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2009 | 1616 | 0.010 |
Why?
|
| Age Factors | 1 | 2019 | 18398 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2009 | 2203 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 2386 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3779 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2011 | 18255 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 4125 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 2457 | 0.010 |
Why?
|
| Incidence | 1 | 2019 | 21355 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 11076 | 0.010 |
Why?
|
| Zebrafish | 1 | 2011 | 3007 | 0.010 |
Why?
|
| RNA Interference | 1 | 2007 | 2832 | 0.010 |
Why?
|
| Alleles | 1 | 2009 | 6864 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 2872 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 23996 | 0.010 |
Why?
|
| Cell Movement | 1 | 2009 | 5205 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 17904 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 11120 | 0.010 |
Why?
|
| Insulin | 1 | 2009 | 6597 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 5672 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2009 | 12794 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 14417 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2009 | 18966 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2007 | 5799 | 0.010 |
Why?
|
| Mice | 2 | 2010 | 81539 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2009 | 4878 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2009 | 11530 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 13642 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 5315 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 21019 | 0.000 |
Why?
|